Larimar Therapeutics GAAP EPS of -$0.29 beats by $0.06
- Larimar Therapeutics press release (LRMR): Q3 GAAP EPS of -$0.29 beats by $0.06.
- Cash, cash equivalents and marketable securities totaled $128.7M as of September 30, 2026; cash runway projected into late Q2 2027.
- Net loss of $31.1M, down 35% Y/Y.
Recommended For You
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
Black Friday: Create a Free Seeking Alpha Account
See what's moving the market with unlimited news access, and get 20% off your first year of any Seeking Alpha service.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.